Literature DB >> 6222908

The effect of piperacillin dose on elimination kinetics in renal impairment.

G R Aronoff, R S Sloan, M E Brier, F C Luft.   

Abstract

The effect of drug dose on piperacillin elimination kinetics was examined in 27 adult subjects with varying renal function. Piperacillin, 15 mg/kg or 60 mg/kg, was given by bolus intravenous injection. The elimination half-life (t1/2) increased five-fold and plasma clearance (Clp) decreased by 80% in patients with renal failure. Both parameters were dose dependent in patients with normal renal function, but not in patients with renal insufficiency. Piperacillin dose dependent elimination is due primarily to capacity limited renal excretion.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6222908     DOI: 10.1007/bf00609901

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  10 in total

1.  Dose dependence of piperacillin pharmacokinetics.

Authors:  T Bergan; J D Williams
Journal:  Chemotherapy       Date:  1982       Impact factor: 2.544

2.  Pharmacokinetics of piperacillin in renal failure.

Authors:  C R George; J Burgoyne; G R Funnell; P Robinson; P Collignon; K Meads; M D Guinness
Journal:  Med J Aust       Date:  1981-01-10       Impact factor: 7.738

3.  In vitro and in vivo antibacterial activity of T-1220, a new semisynthetic penicillin.

Authors:  K Ueo; Y Fukuoka; T Hayashi; T Yasuda; H Taki; M Tai; Y Watanabe; I Saikawa; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1977-10       Impact factor: 5.191

4.  Piperacillin, a new penicillin active against many bacteria resistant to other penicillins.

Authors:  K P Fu; H C Neu
Journal:  Antimicrob Agents Chemother       Date:  1978-03       Impact factor: 5.191

5.  Piperacillin: human pharmacokinetics after intravenous and intramuscular administration.

Authors:  T B Tjandramaga; A Mullie; R Verbesselt; P J De Schepper; L Verbist
Journal:  Antimicrob Agents Chemother       Date:  1978-12       Impact factor: 5.191

Review 6.  Overview of acylureidopenicillin pharmacokinetics.

Authors:  T Bergan
Journal:  Scand J Infect Dis Suppl       Date:  1981

7.  Mezlocillin dose dependent elimination kinetics in renal impairment.

Authors:  G R Aronoff; R S Sloan; R A Stanish; N S Fineberg
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

8.  Pharmacokinetics of piperacillin in patients with moderate renal failure and in patients undergoing hemodialysis.

Authors:  J A Giron; B R Meyers; S Z Hirschman; E Srulevitch
Journal:  Antimicrob Agents Chemother       Date:  1981-02       Impact factor: 5.191

9.  Biliary concentrations of piperacillin in patients undergoing cholecystectomy.

Authors:  J A Giron; B R Meyers; S Z Hirschman
Journal:  Antimicrob Agents Chemother       Date:  1981-02       Impact factor: 5.191

10.  Piperacillin pharmacokinetics in subjects with chronic renal failure.

Authors:  M I Thompson; M E Russo; J M Matsen; E Atkin-Thor
Journal:  Antimicrob Agents Chemother       Date:  1981-03       Impact factor: 5.191

  10 in total
  10 in total

1.  Nonlinear pharmacokinetics of piperacillin in healthy volunteers--implications for optimal dosage regimens.

Authors:  Jürgen B Bulitta; Martina Kinzig; Verena Jakob; Ulrike Holzgrabe; Fritz Sörgel; Nicholas H G Holford
Journal:  Br J Clin Pharmacol       Date:  2010-11       Impact factor: 4.335

2.  Identification of optimal renal dosage adjustments for traditional and extended-infusion piperacillin-tazobactam dosing regimens in hospitalized patients.

Authors:  N Patel; M H Scheetz; G L Drusano; T P Lodise
Journal:  Antimicrob Agents Chemother       Date:  2009-10-26       Impact factor: 5.191

Review 3.  Drug dosage in patients during continuous renal replacement therapy. Pharmacokinetic and therapeutic considerations.

Authors:  P Reetze-Bonorden; J Böhler; E Keller
Journal:  Clin Pharmacokinet       Date:  1993-05       Impact factor: 6.447

4.  Population Pharmacokinetics of Piperacillin in Sepsis Patients: Should Alternative Dosing Strategies Be Considered?

Authors:  Maria Goul Andersen; Anders Thorsted; Merete Storgaard; Anders N Kristoffersson; Lena E Friberg; Kristina Öbrink-Hansen
Journal:  Antimicrob Agents Chemother       Date:  2018-04-26       Impact factor: 5.191

5.  Piperacillin and tazobactam exhibit linear pharmacokinetics after multiple standard clinical doses.

Authors:  B Auclair; M P Ducharme
Journal:  Antimicrob Agents Chemother       Date:  1999-06       Impact factor: 5.191

6.  Population pharmacokinetics of piperacillin at two dose levels: influence of nonlinear pharmacokinetics on the pharmacodynamic profile.

Authors:  Cornelia B Landersdorfer; Jurgen B Bulitta; Carl M J Kirkpatrick; Martina Kinzig; Ulrike Holzgrabe; George L Drusano; Ulrich Stephan; Fritz Sörgel
Journal:  Antimicrob Agents Chemother       Date:  2012-08-20       Impact factor: 5.191

7.  Single-dose pharmacokinetics of piperacillin and tazobactam in infants and children.

Authors:  M D Reed; J Goldfarb; T S Yamashita; E Lemon; J L Blumer
Journal:  Antimicrob Agents Chemother       Date:  1994-12       Impact factor: 5.191

8.  Pharmacokinetics of intravenous piperacillin administration in patients undergoing on-line hemodiafiltration.

Authors:  Kook-Hwan Oh; Chiweon Kim; Hankyu Lee; Hajeong Lee; Ji Yong Jung; Nam Joong Kim; Kyung-Sang Yu; Kwang-Hee Shin; In-Jin Jang; Curie Ahn
Journal:  Antimicrob Agents Chemother       Date:  2009-05-18       Impact factor: 5.191

Review 9.  Piperacillin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  B Holmes; D M Richards; R N Brogden; R C Heel
Journal:  Drugs       Date:  1984-11       Impact factor: 9.546

10.  Kidney failure related to broad-spectrum antibiotics in critically ill patients: secondary end point results from a 1200 patient randomised trial.

Authors:  Jens-Ulrik Stæhr Jensen; Lars Hein; Bettina Lundgren; Morten Heiberg Bestle; Thomas Mohr; Mads Holmen Andersen; Klaus Julius Thornberg; Jesper Løken; Morten Steensen; Zoë Fox; Hamid Tousi; Peter Søe-Jensen; Anne Øberg Lauritsen; Ditte Gry Strange; Nanna Reiter; Katrin Thormar; Paul Christian Fjeldborg; Kim Michael Larsen; Niels-Erik Drenck; Maria Egede Johansen; Lene Ryom Nielsen; Christian Ostergaard; Jesper Kjær; Jesper Grarup; Jens D Lundgren
Journal:  BMJ Open       Date:  2012-03-11       Impact factor: 2.692

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.